Uteroglobin: A potential novel tumor suppressor and molecular therapeutic for prostate cancer

Clinical Prostate Cancer

Volumn 1, Issue 2, 2002, Pages 118-124

  Patierno, Steven R ^a   Manyak, Michael J ^a   Fernandez, Patricia M ^a   Baker, Angela ^a   Weeraratna, Ashani T ^a   Chou, David S ^a   Szlyk, Greg ^a   Shane Geib, K ^a   Walsh, Christopher ^a   Patteras, John ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; CC10; Chorioallantoic membrane nodule assay; Invasion; Metastasis; Tumor

Indexed keywords

RECOMBINANT HUMAN UTEROGLOBIN; UNCLASSIFIED DRUG; UTEROGLOBIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AORTA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOSTASIS; DRUG MECHANISM; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LUNG CANCER; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PILOT STUDY; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN EXPRESSION; REVIEW; STATISTICAL ANALYSIS; TUMOR CELL CULTURE; TUMOR VOLUME; UTERUS CANCER; VASCULARIZATION;

EID: 12444267904     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2002.n.014     Document Type: Article

References (29)

1. Cancer facts and figures. American Cancer Society 2002.
2. Kohn EC. Invasion and metastasis: biology and clinical potential. Pharmacol Ther 1991; 52:235-244.
3. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993; 71:1368-1383.
4. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55:1856-1862.
5. Liotta LA, Stetler-Stevenson WG, Steeg PS. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 1991; 9:543-551.
6. Miele L, Cordella-Miele E, Mantile G, et al. Uteroglobin and uteroglobin-like proteins: the uteroglobin family of proteins. J Endocrinol Invest 1994; 17:679-692.
7. Zhang Z, Zimonjic DB, Popescu NC, et al. Human uteroglobin gene: structure, subchromosomal localization, and polymorphism. DNA Cell Biol 1997; 16:73-83.
8. Miele L, Cordella-Miele E, Mukherjee AB. Uteroglobin: structure, molecular biology, and new perspectives on its function as a phospholipase A2 inhibitor. Endocr Rev 1987; 8:474-490.
9. Peri A, Cordella-Miele E, Miele L, et al. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. J Clin Invest 1993; 92:2099-2109.
10. Plopper CG, Hill LH, Mariassy AT. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res 1980; 1:171-180.
11. Leyton J, Manyak MJ, Mukherjee AB, et al. Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium. Cancer Res 1994; 54:3696-3699.
12. Broers JL, Jensen SM, Travis WD, et al. Expression of surfactant associated protein-A and Clara cell 10 kilodalton mRNA in neoplastic and non-neoplastic human lung tissue as detected by in situ hybridization. Lab Invest 1992; 66:337-346.
13. Linnoila RI, Jensen SM, Steinberg SM, et al. Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol 1992; 97:233-243.
14. Sandmoller A, Halter R, Suske G, et al. A transgenic mouse model for lung adenocarcinoma. Cell Growth Differ 1995; 6:97-103.
15. Weeraratna AT, Cajigas JA, Schwartz A, et al. Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. Clin Cancer Res 1997; 3:2295-2300.
16. Szabo E, Goheer A, Witschi H, et al. Overexpression of CC10 modifies neoplastic potential in lung cancer cells. Cell Growth Differ 1998; 9:475-485.
17. Peri A, Bonaccorsi L, Muratori M, et al. Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. Int J Cancer 2000; 88:525-534.
18. Zhang Z, Kundu GC, Panda D, et al. Loss of transformed phenotype in cancer cells by overexpression of the uteroglobin gene. Proc Natl Acad Sci USA 1999; 96:3963-3968.
19. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma. Amer J Pathology 2002; 160:2169-2180.
20. Beer D, Kardia S, Huang C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-824.
21. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7:147-154.
22. Zhang Z, Kundu GC, Yuan CJ, et al. Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 1997; 276:1408-1412.
23. Akiyama SK, Olden K, Yamada KM. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev 1995; 14:173-189.
24. Knutson JR, Iida J, Fields GB, et al. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 1996; 7:383-396.
25. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69:11-25.
26. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. Faseb J 1997; 11:234-247.
27. Reich R, Martin GR. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996; 51:1-17.
28. Attiga F, Fernandez P, Weeraratna A, et al. Inhibitors of prostaglandin synthesis inhibit prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Canc Res 2000: 60;4629-4637.
29. Kundu GC, Mantile G, Miele L, et al. Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proc Natl Acad Sci U S A 1996; 93:2915-2919.